KALA BIO, Inc. (0JQ2.L)
| Previous close | 7.22 |
| Open | 7.01 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 6.85 - 7.04 |
| 52-week range | 5.27 - 19.48 |
| Volume | |
| Avg. volume | 320 |
| Market cap | N/A |
| Beta (5Y monthly) | -2.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 Aug 2024 - 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireKALA BIO Announces $12,500,000 Private Placement
ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeema
- GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be av
Insider MonkeyWall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)
European stocks started the day on May 21 with a slightly weaker note, marking a retreat from their recent impressive performance, with attention now shifting towards the upcoming earnings report from NVIDIA. The Stoxx 600 index dipped by 0.2%, showing a predominantly negative trend across most sectors, while futures for US equities remained relatively unchanged. […]
